ArticleNature medicine2026
EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
D2C7-ATC is a recombinant antibody-toxin conjugate (ATC) targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII). We conducted a single-arm, single-site, open-label phase 1 trial evaluating a single infusion of D2C7-ATC via convection-enhanced delivery in the enhancing disease of 81 patients with biopsy-confirmed recurrent malignant glioma. The primary objective was to determine toxicity and the recommended phase 2 dose (RP2D) of D2C7-ATC. Secondary objectives included describing overall survival (OS) and assessing the association between EGFR expression and OS. The median overall survival (mOS) was 7.9 months among 72 patients with isocitrate dehydrogenase wild-type recurrent glioblastoma (IDHwt rGBM), including 35 patients in the dose-escalation stage (40 to 35,032 ng ml
Identifiers
42888247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.